Skip to main content

Advertisement

SpringerLink
Log in

Antifungal therapy for the treatment of CNS infections

  • Review
  • Published:
Current Fungal Infection Reports Aims and scope Submit manuscript

Abstract

Purpose of review

A review of existing and emerging therapies for the treatment of fungal infections of the CNS is presented, highlighting more recent studies. Newly authorized and emerging therapies and the data surrounding their use are also introduced.

Recent findings

Early data suggests Ibrexafungerp, a newly released antifungal for the treatment of vulvovaginal candidiasis, does not have a significant role in the treatment of CNS infections. Combination therapy including therapy with terbinafine appears promising for difficult-to-treat fungal infections of the CNS. Antifungal treatment remains pathogen-specific but in resource-available areas, liposomal amphotericin B or triazole are the first line for CNS fungal infections. A one-time liposomal amphotericin B infusion followed by flucytosine and fluconazole can be considered for persons living with HIV in resource-poor areas.

Summary

Pathogen-specific management is reviewed and the latest evidence surrounding treatment is discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Patel M, Chen J, Kim S, Garg S, Flannery B, Haddadin Z, et al. Analysis of MarketScan Data for Immunosuppressive Conditions and Hospitalizations for Acute Respiratory Illness. United States Emerg Infect Dis. 2020Aug;26(8):1720–30.

    Article  CAS  PubMed  Google Scholar 

  2. Multistate outbreak of fungal infection associated with injection of methylprednisolone acetate solution from a single compounding pharmacy-United States, 2012. MMWR Morb Mortal Wkly Rep. 2012 61(41):839–42

  3. Smith DJ, Gold JAW, Chiller T, Bustamante ND, Marinissen MJ, Rodriquez GG, et al. Update on Outbreak of Fungal Meningitis among U.S. Residents who Received Epidural Anesthesia at Two Clinics in Matamoros, Mexico. Clin Infect Dis. https://doi.org/10.1093/cid/ciad570

  4. Gushiken AC, Saharia KK, Baddley JW. Cryptococcosis. Infect Dis Clin North Am. 2021;35(2):493–514.

    Article  PubMed  Google Scholar 

  5. Mazi PB, Sahrmann JM, Olsen MA, Coler-Reilly A, Rauseo AM, Pullen M, et al. The geographic distribution of dimorphic mycoses in the United States for the modern era. Clin Infect Dis. 2023;76(7):1295–301.

    Article  PubMed  Google Scholar 

  6. Nau R, Sörgel F, Eiffert H. Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections. Clin Microbiol Rev. 2010;23(4):858–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Felton T, Troke PF, Hope WW. Tissue penetration of antifungal agents. Clin Microbiol Rev. 2014;27(1):68–88.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Kaiser AB, McGee ZA. Aminoglycoside therapy of gram-negative bacillary meningitis. N Engl J Med. 1975;293(24):1215–20.

    Article  CAS  PubMed  Google Scholar 

  9. Quagliarello VJ, Long WJ, Scheld WM. Morphologic alterations of the blood-brain barrier with experimental meningitis in the rat Temporal sequence and role of encapsulation. J Clin Invest. 1986;77(4):1084–95.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Haddad N, Carr M, Balian S, Lannin J, Kim Y, Toth C, et al. The blood-brain barrier and pharmacokinetic/pharmacodynamic optimization of antibiotics for the treatment of central nervous system infections in adults. Antibiotics (Basel). 2022Dec 19;11(12):1843.

    Article  CAS  PubMed  Google Scholar 

  11. Sorensen KN, Sobel RA, Clemons KV, Calderon L, Howell KJ, Irani PR, et al. Comparative efficacies of terbinafine and fluconazole in treatment of experimental coccidioidal meningitis in a rabbit model. Antimicrob Agents Chemother. 2000;44(11):3087–91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Jenks JD, Seidel D, Cornely OA, Chen S, van Hal S, Kauffman C, et al. Voriconazole plus terbinafine combination antifungal therapy for invasive Lomentospora prolificans infections: analysis of 41 patients from the FungiScope® registry 2008–2019. Clin Microbiol Infect. 2020;26(6):784.e1-784.e5.

    Article  CAS  PubMed  Google Scholar 

  13. Henao-Martínez AF, Castillo-Mancilla JR, Barron MA, Nichol AC. Combination Antifungal Therapy in the Treatment of Scedosporium apiospermum Central Nervous System Infections. Case Rep Infect Dis. 2013;2013:589490.

    PubMed  PubMed Central  Google Scholar 

  14. (2021) HIGHLIGHTS OF PRESCRIBING INFORMATION- BREXAFEMME® (ibrexafungerp tablets). https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214900s002lbl.pdf. Accessed 01 Jan. 2024

  15. Wiederhold NP. Review of the novel investigational antifungal olorofim. J Fungi (Basel). 2020;6(3):122.

    Article  CAS  PubMed  Google Scholar 

  16. Wiederhold NP, Najvar LK, Jaramillo R, Olivo M, Birch M, Law D, et al. The orotomide olorofim is efficacious in an experimental model of central nervous system coccidioidomycosis. Antimicrob Agents Chemother. 2018;62(9):e00999-e1018.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Petraitiene R, Petraitis V, Maung BBW, Mansbach RS, Hodges MR, Finkelman MA, et al. Efficacy and pharmacokinetics of fosmanogepix (APX001) in the treatment of candida endophthalmitis and hematogenous meningoencephalitis in nonneutropenic rabbits. Antimicrob Agents Chemother. 2021;65(3):e01795-e1820.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Shaw KJ, Schell WA, Covel J, Duboc G, Giamberardino C, Kapoor M, et al. In vitro and in vivo evaluation of APX001A/APX001 and other Gwt1 inhibitors against cryptococcus. Antimicrob Agents Chemother. 2018;62(8):e00523-e618.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Alkhazraji S, Gebremariam T, Alqarihi A, Gu Y, Mamouei Z, Singh S, et al. Fosmanogepix (APX001) is effective in the treatment of immunocompromised mice infected with invasive pulmonary scedosporiosis or disseminated fusariosis. Antimicrob Agents Chemother. 2020;64(3):e01735-e1819.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Schwartz S, Kontoyiannis DP, Harrison T, Ruhnke M. Advances in the diagnosis and treatment of fungal infections of the CNS. Lancet Neurol. 2018;17(4):362–72.

    Article  PubMed  Google Scholar 

  21. Molloy SF, Kanyama C, Heyderman RS, Loyse A, Kouanfack C, Chanda D, et al. Antifungal Combinations for Treatment of Cryptococcal Meningitis in Africa. N Engl J Med. 2018;378(11):1004–17.

    Article  CAS  PubMed  Google Scholar 

  22. Lawrence DS, Youssouf N, Molloy SF, Alanio A, Alufandika M, Boulware DR, et al. AMBIsome Therapy Induction OptimisatioN (AMBITION): high dose ambisome for cryptococcal meningitis induction therapy in sub-Saharan Africa: study protocol for a phase 3 randomised controlled non-inferiority trial. Trials. 2018;19(1):649.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Guidelines for diagnosing, preventing and managing cryptococcal disease among adults, adolescents and children living with HIV. Geneva: World Health Organization; 2022. Regularlly updated and notable guidelines for treatment of cryptococcus.

  24. Beardsley J, Sorrell TC, Chen SC. Central nervous system cryptococcal infections in non-HIV infected patients. J Fungi (Basel). 2019;5(3):71.

    Article  CAS  PubMed  Google Scholar 

  25. Ngan NTT, Flower B, Day JN. Treatment of cryptococcal meningitis: how have we got here and where are we going. Drugs. 2022;82(12):1237–49.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Beardsley J, Wolbers M, Kibengo FM, Ggayi AB, Kamali A, Cuc NT, et al. Adjunctive dexamethasone in HIV-associated cryptococcal meningitis. N Engl J Med. 2016;374(6):542–54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Ngan NTT, Le Thanh Hoang N, Vi Vi NN, Van NTT, Mai NTH, Van Anh D, et al. An open label randomized controlled trial of tamoxifen combined with amphotericin B and fluconazole for cryptococcal meningitis. Elife. 2021;28(10):e68929.

    Article  Google Scholar 

  28. Rhein J, Morawski BM, Hullsiek KH, Nabeta HW, Kiggundu R, Tugume L, et al. Efficacy of adjunctive sertraline for the treatment of HIV-associated cryptococcal meningitis: an open-label dose-ranging study. Lancet Infect Dis. 2016;16(7):809–18.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. van der Horst CM, Saag MS, Cloud GA, Hamill RJ, Graybill JR, Sobel JD, et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N Engl J Med. 1997;337(1):15–21.

    Article  PubMed  Google Scholar 

  30. Hoenigl M, Sprute R, Egger M, Arastehfar A, Cornely OA, Krause R, et al. The antifungal pipeline: fosmanogepix, ibrexafungerp, olorofim, opelconazole, and rezafungin. Drugs. 2021;81(15):1703–29.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Cordeiro RA, Evangelista AJJ, Serpa R, Marques FJF, Melo CVS, Oliveira JS, et al. Inhibition of heat-shock protein 90 enhances the susceptibility to antifungals and reduces the virulence of Cryptococcus neoformans/Cryptococcus gattii species complex. Microbiology. 2016;162(2):309–17.

    Article  CAS  PubMed  Google Scholar 

  32. Matthews RC, Rigg G, Hodgetts S, Carter T, Chapman C, Gregory C, et al. Preclinical assessment of the efficacy of mycograb, a human recombinant antibody against fungal HSP90. Antimicrob Agents Chemother. 2003;47(7):2208–16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Nooney L, Matthews RC, Burnie JP. Evaluation of Mycograb, amphotericin B, caspofungin, and fluconazole in combination against Cryptococcus neoformans by checkerboard and time-kill methodologies. Diagn Microbiol Infect Dis. 2005;51(1):19–29.

    Article  CAS  PubMed  Google Scholar 

  34. Marcyk PT, LeBlanc EV, Kuntz DA, Xue A, Ortiz F, Trilles R, et al. Fungal-selective resorcylate aminopyrazole Hsp90 inhibitors: optimization of whole-cell anticryptococcal activity and insights into the structural origins of cryptococcal selectivity. J Med Chem. 2021;64(2):1139–69.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Warrilow AG, Parker JE, Price CL, Nes WD, Garvey EP, Hoekstra WJ, et al. The investigational drug VT-1129 is a highly potent inhibitor of cryptococcus species CYP51 but only weakly inhibits the human enzyme. Antimicrob Agents Chemother. 2016;60(8):4530–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Smilnak GJ, Charalambous LT, Cutshaw D, Premji AM, Giamberardino CD, Ballard CG, et al. Novel Treatment of Cryptococcal Meningitis via Neurapheresis Therapy. J Infect Dis. 2018;218(7):1147–54.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Fennelly AM, Slenker AK, Murphy LC, Moussouttas M, DeSimone JA. Candida cerebral abscesses: a case report and review of the literature. Med Mycol. 2013;51(7):779–84.

    Article  PubMed  Google Scholar 

  38. Sánchez-Portocarrero J, Pérez-Cecilia E, Corral O, Romero-Vivas J, Picazo JJ. The central nervous system and infection by Candida species. Diagn Microbiol Infect Dis. 2000;37(3):169–79.

    Article  PubMed  Google Scholar 

  39. KE, Black, LR, Baden. Fungal infections of the CNS: treatment strategies for the immunocompromised patient. CNS Drugs. 2007;21(4):293–318 (Dated but excellent review of CNS fungal infections and treatments).

  40. Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62(4):e1-50.

    Article  PubMed  Google Scholar 

  41. Pappas PG, Rex JH, Sobel JD, Filler SG, Dismukes WE, Walsh TJ, et al. Guidelines for treatment of candidiasis. Clin Infect Dis. 2004;38(2):161–89.

    Article  PubMed  Google Scholar 

  42. Thompson GR, Young JH. Aspergillus Infections. N Engl J Med. 2021;385(16):1496–509.

    Article  CAS  PubMed  Google Scholar 

  43. Patterson TF, Thompson GR, Denning DW, Fishman JA, Hadley S, Herbrecht R, et al. Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;63(4):e1–60.

    Article  PubMed  PubMed Central  Google Scholar 

  44. McCarthy M, Rosengart A, Schuetz AN, Kontoyiannis DP, Walsh TJ. Mold infections of the central nervous system. N Engl J Med. 2014;371(2):150–60.

    Article  PubMed  PubMed Central  Google Scholar 

  45. van der Linden JW, Camps SM, Kampinga GA, Arends JP, Debets-Ossenkopp YJ, Haas PJ, et al. Aspergillosis due to voriconazole highly resistant Aspergillus fumigatus and recovery of genetically related resistant isolates from domiciles. Clin Infect Dis. 2013;57(4):513–20.

    Article  PubMed  Google Scholar 

  46. Majdick K, Kaye K, Shorman MA. Central nervous system blastomycosis clinical characteristics and outcomes. Med Mycol. 2021;59(1):87–92.

    Article  PubMed  Google Scholar 

  47. Bakleh M, Aksamit AJ, Tleyjeh IM, Marshall WF. Successful treatment of cerebral blastomycosis with voriconazole. Clin Infect Dis. 2005;40(9):e69-71.

    Article  PubMed  Google Scholar 

  48. McBride JA, Gauthier GM, Klein BS. Clinical manifestations and treatment of blastomycosis. Clin Chest Med. 2017;38(3):435–49.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Stavrakis C, Narayan A, Voronel O. Cerebral blastomycosis: radiologic-pathologic correlation of solitary CNS blastomycosis mass-like infection. J Clin Imaging Sci. 2015;5:30.

    Article  PubMed  PubMed Central  Google Scholar 

  50. Chapman SW, Dismukes WE, Proia LA, Bradsher RW, Pappas PG, Threlkeld MG, et al. Clinical practice guidelines for the management of blastomycosis: 2008 update by the Infectious Diseases Society of America. Clin Infect Dis. 2008;46(12):1801–12.

    Article  CAS  PubMed  Google Scholar 

  51. Miller R, Assi M. Endemic fungal infections in solid organ transplant recipients-Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019;33(9):e13553 (Notable guideline on endemic mycosis with a focus on solid organ transplant recipients, but with a wider application. Apply style).

    Article  PubMed  Google Scholar 

  52. Bariola JR, Perry P, Pappas PG, Proia L, Shealey W, Wright PW, et al. Blastomycosis of the central nervous system: a multicenter review of diagnosis and treatment in the modern era. Clin Infect Dis. 2010;50(6):797–804.

    Article  PubMed  Google Scholar 

  53. Wheat J, Myint T, Guo Y, Kemmer P, Hage C, Terry C, et al. Central nervous system histoplasmosis: Multicenter retrospective study on clinical features, diagnostic approach and outcome of treatment. Medicine (Baltimore). 2018;97(13):e0245.

    Article  CAS  PubMed  Google Scholar 

  54. Haynes RR, Connolly PA, Durkin MM, LeMonte AM, Smedema ML, Brizendine E, et al. Antifungal therapy for central nervous system histoplasmosis, using a newly developed intracranial model of infection. J Infect Dis. 2002;185(12):1830–2.

    Article  PubMed  Google Scholar 

  55. Restrepo A, Tobón A, Clark B, Graham DR, Corcoran G, Bradsher RW, et al. Salvage treatment of histoplasmosis with posaconazole. J Infect. 2007;54(4):319–27.

    Article  PubMed  Google Scholar 

  56. Srinivasan J, Ooi WW. Successful treatment of histoplasmosis brain abscess with voriconazole. Arch Neurol. 2008;65(5):666–7.

    Article  PubMed  Google Scholar 

  57. Dhawan J, Verma P, Sharma A, Ramam M, Kabra SK, Gupta S. Disseminated cutaneous histoplasmosis in an immunocompetent child, relapsed with itraconazole, successfully treated with voriconazole. Pediatr Dermatol. 2010;27(5):549–51.

    Article  PubMed  Google Scholar 

  58. Clark B, Foster R, Tunbridge A, Green S. A case of disseminated histoplasmosis successfully treated with the investigational drug posaconazole. J Infect. 2005;51(3):e177–80.

    Article  CAS  PubMed  Google Scholar 

  59. Bouza E, Dreyer JS, Hewitt WL, Meyer RD. Coccidioidal meningitis An analysis of thirty-one cases and review of the literature. Medicine. 1981;60(3):139–72.

    Article  CAS  PubMed  Google Scholar 

  60. Galgiani JN, Ampel NM, Blair JE, Catanzaro A, Geertsma F, Hoover SE, et al. 2016 Infectious Diseases Society of America (IDSA) Clinical Practice Guideline for the Treatment of Coccidioidomycosis. Clin Infect Dis. 2016;63(6):e112-46 (* Notable guideline).

    Article  PubMed  Google Scholar 

  61. Chowdhary A, Meis JF, Guarro J, de Hoog GS, Kathuria S, Arendrup MC, et al. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of systemic phaeohyphomycosis: diseases caused by black fungi. Clin Microbiol Infect. 2014;20(Suppl 3):47–75 (Excellent Guideline on phaeohyphomycosis).

    Article  CAS  PubMed  Google Scholar 

  62. Ganesan V, Hallur V, Velvizhi S, Rajendran T. Cerebral phaeohyphomycosis due to Cladophialophora bantiana: case report and systematic review of cases. Infection. 2023 . Epub ahead of print.

  63. Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis. 2005;41(5):634–53.

    Article  PubMed  Google Scholar 

  64. Jeong W, Keighley C, Wolfe R, Lee WL, Slavin MA, Kong DCM, et al. The epidemiology and clinical manifestations of mucormycosis: a systematic review and meta-analysis of case reports. Clin Microbiol Infect. 2019;25(1):26–34.

    Article  CAS  PubMed  Google Scholar 

  65. Muthu V, Agarwal R, Rudramurthy SM, Thangaraju D, Shevkani MR, Patel AK, et al. Multicenter case-control study of COVID-19-associated mucormycosis outbreak. India Emerg Infect Dis. 2023;29(1):8–19.

    Article  PubMed  Google Scholar 

  66. Cornely OA, Alastruey-Izquierdo A, Arenz D, Chen SCA, Dannaoui E, Hochhegger B, et al. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect Dis. 2019;19(12):e405–21 (Excellent guideline on Mucormycosis).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Highlights of Prescribing Information - Cresemba [Internet]. Food and Drug Adminstration; [cited 2021 Jan 2]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207500s015,207501s013lbl.pdf

  68. Kainer MA, Reagan DR, Nguyen DB, Wiese AD, Wise ME, Ward J, et al. Fungal infections associated with contaminated methylprednisolone in Tennessee. N Engl J Med. 2012;367(23):2194–203.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Lewis Katz School of Medicine at, Temple University, 3322 N Broad Street Suite 203, Philadelphia, PA, USA

    Moeen Aboabdo & Aaron Mishkin

Authors
  1. Moeen Aboabdo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Aaron Mishkin
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

M.A and A.M wrote the manuscript text, A.M. prepared table 1. All authors reviewed the manuscript.

Corresponding author

Correspondence to Moeen Aboabdo.

Ethics declarations

Competing interests

The authors declare no competing interests.

Conflict of interest

Moeen Aboabdo declares that he has no conflict of interest. Aaron Mishkin previously served on an advisory board for Takeda, outside the submitted work.

Human and animal rights and informed consent.

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Aboabdo, M., Mishkin, A. Antifungal therapy for the treatment of CNS infections. Curr Fungal Infect Rep (2024). https://doi.org/10.1007/s12281-024-00492-6

Download citation

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12281-024-00492-6

Keywords

Search

Navigation